# OnCo record polo (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/polo/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "polo", "NCT02184195" ;
  schema:name "POLO"@en ;
  schema:description "The first biomarker-directed drug approval in pancreatic cancer, for the roughly 5-7% with inherited BRCA mutations, though it did not extend overall survival."@en ;
  schema:url <https://onco.cc/trials/polo/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02184195>, <https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22LYNPARZA%22>, <https://doi.org/10.1200/JCO.21.01604> ;
  onco:status "mixed" ;
  onco:phase "3" ;
  schema:startDate "2014-12-16" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/brca-palb2-pdac/> ;
  onco:technologies <https://onco.cc/technologies/parp-inhibitor/>, <https://onco.cc/technologies/germline-testing/> ;
  onco:targets <https://onco.cc/targets/brca/>, <https://onco.cc/targets/parp/> ;
  onco:drugs <https://onco.cc/drugs/olaparib/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:trials <https://onco.cc/trials/panoptimox-prodige-35/>, <https://onco.cc/trials/nct05093231/> ;
  onco:people <https://onco.cc/people/talia-golan/>, <https://onco.cc/people/hedy-kindler/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-golan-brca-pancreatic-platinum-survival-bjc-2014/>, <https://onco.cc/key-papers/paper-park-hrd-pancreatic-platinum-ccr-2020/> .